State Street Global Advisors Ends Substantial Stake in Mesoblast Limited as of July 2026

Overview of Mesoblast Limited’s Business Model and Market Position

Mesoblast Limited is an Australian biopharmaceutical company specialising in regenerative medicine therapies utilizing proprietary cell therapy technology. The company develops off-the-shelf, allogeneic cell therapy products aimed at treating multiple medical conditions across diverse therapeutic areas. As a clinical- to commercial-stage biotech firm, Mesoblast’s revenue streams primarily depend on advancing clinical trials, securing regulatory approvals, and eventual commercialisation of its therapeutic candidates, alongside research collaborations and licensing agreements that may yield milestone and royalty income.

Operating in the competitive regenerative medicine and cell therapy industry, Mesoblast faces critical success factors such as regulatory pathways, clinical trial outcomes, and intellectual property protection. Its Sydney headquarters serves as the operational hub for a business model increasingly reliant on international partnerships and global regulatory strategies to commercialise its cell therapy platforms across multiple disease indications. The sector’s dynamics include evolving FDA and TGA regulatory frameworks, rising institutional investor interest, and intensifying competition from global cell therapy developers.

State Street’s Shareholding Changes and Cessation of Substantial Interest

State Street Global Advisors and its subsidiaries, including State Street Bank and Trust Company and State Street Global Advisors Limited, maintained a substantial interest in Mesoblast Limited until 22 July 2026. The last substantial holding notice was dated 6 March 2026 and submitted on 10 March 2026, indicating a significant shareholding position held for approximately four and a half months before dropping below the statutory threshold. The formal update filed on 24 July 2026 confirms the cessation of State Street’s substantial holder status, marking a significant shift in the institutional ownership landscape of the ASX-listed regenerative medicine company.

This transition aligns with broader market activity in biotech and cell therapy sectors, where institutional investors regularly rebalance portfolios based on clinical progress, regulatory developments, and market sentiment. State Street Corporation, headquartered at 1 Congress Street, Boston, Massachusetts, and its Australian subsidiary State Street Global Advisors, Australia, Limited, operate across multiple asset classes globally. The cessation of substantial holder status reflects a reduction below the five percent disclosure threshold and does not necessarily indicate a full exit from Mesoblast shareholding.

Detailed Share Transactions from March to July 2026

Between 9 March 2026 and 10 March 2026, State Street Bank and Trust Company executed numerous transactions affecting its relevant interest in Mesoblast ordinary shares. These included multiple collateral receipt events and stock lending arrangements, with transaction sizes ranging from 13 to 110,940 ordinary shares. These activities, primarily classified as collateral received and stock lending, suggest usage of Mesoblast shares as part of securities lending and collateral management rather than outright sales or purchases.

Transaction records show increases in relevant interests on certain dates—266, 353, 25,489, 17,144, 292,876, and 91,297 ordinary shares respectively—offset by larger decreases across other transactions. This complex repositioning reflects adjustments across different funds and managed accounts within State Street Global Advisors. The net effect by 22 July 2026 was a reduction of State Street’s relevant interest below the five percent substantial holding threshold.

Stock Lending and Collateral Management Practices

State Street’s stock lending and collateral receipt transactions align with standard institutional asset management and custody operations. Securities lending involves temporarily loaning shares to third parties, typically short sellers or market participants, in exchange for collateral securing the loan. These arrangements enable custodians and asset managers to generate additional returns while maintaining portfolio positions. The frequency and scale of collateral receipts in the Mesoblast transaction log indicate active securities lending management during March 2026.

This stock lending framework offers institutional flexibility and incremental revenue but can influence disclosed relevant interests, particularly when lending affects voting rights or economic exposure. For Mesoblast shareholders, active securities lending involving substantial share portions may indicate strong institutional demand to borrow shares, potentially facilitating short positions or other market strategies within the investment ecosystem.

Regulatory Requirements for Substantial Holder Disclosures

Under the Corporations Act 2001, entities with relevant interests in voting securities reaching or exceeding five percent of a listed company must lodge substantial holding notices with the company and the Australian Securities Exchange within two business days. Similarly, when a substantial holder’s interest falls below five percent, they must notify the company within two business days of cessation. State Street’s 24 July 2026 notice complies with these disclosure obligations under section 671B of the Act.

Relevant interest includes direct and indirect voting securities interests, including those arising from agreements or arrangements affecting voting rights or share disposal. State Street’s multiple subsidiaries—including State Street Bank and Trust Company, State Street Global Advisors Limited, and State Street Global Advisors, Australia, Limited—are considered separate persons but their interests may be aggregated as associates under section 9 of the Act. This notification process ensures market transparency regarding major shareholding shifts that can influence corporate governance and strategic decisions.

Impact on Mesoblast Investors and Market Sentiment

State Street’s cessation of substantial holding in Mesoblast holds significance for retail and institutional investors tracking the company’s shareholder register. Substantial holders often represent long-term strategic investors and major institutional funds capable of influencing governance through shareholder meetings and director elections. State Street’s reduction could reflect portfolio rebalancing or deliberate Mesoblast exposure reduction across its managed funds. Without further details, it is unclear if this signals negative sentiment or routine portfolio optimisation.

Mesoblast operates in a sector where institutional investor sentiment is sensitive to clinical milestones, regulatory approvals, partnership announcements, and competitive developments. Changes in substantial holders indicate investment allocation shifts rather than direct commentary on operational performance or commercial prospects. Ongoing monitoring of substantial holder notices will provide insight into institutional positioning in Mesoblast Limited.

State Street Global Advisors’ Role in Global Asset Management

State Street Global Advisors, a subsidiary of State Street Corporation based in Boston, Massachusetts, is among the world’s largest asset managers, overseeing trillions in assets across equity, fixed income, alternatives, and ETFs for institutional and retail clients worldwide. Its services include investment management, custody, administration, and clearing, making it a key infrastructure provider in global financial markets. The decision to cease substantial interest in Mesoblast reflects dynamic portfolio management across its extensive fund offerings.

State Street’s Australian operations, managed through subsidiaries such as State Street Global Advisors, Australia, Limited (based in Dublin, Ireland) and its parent company at One Congress Street, Boston, represent major institutional capital allocators in Australian equities. Its involvement with Mesoblast shares through European and North American subsidiaries highlights the global nature of its investment operations. The cessation of substantial holding status does not preclude future investments, as portfolio adjustments are routine based on market conditions and investment strategies.

Recommendations for Mesoblast Shareholders

Mesoblast investors should continue monitoring subsequent substantial holder notices filed with the company to observe changes in institutional ownership. The Australian Securities Exchange maintains a public register of these notices, enabling tracking of major ownership shifts. Future filings may reveal whether other institutional investors increase stakes following State Street’s reduction, potentially indicating renewed confidence in Mesoblast’s regenerative medicine platform and clinical pipeline. Additionally, investors should watch for company announcements on clinical trial results, regulatory interactions with the Therapeutic Goods Administration and international regulators, partnership developments, and financing activities that could affect institutional investment sentiment.

The regenerative medicine sector is rapidly evolving, with regulatory approvals, clinical efficacy data, and manufacturing scale-up success heavily influencing investor sentiment and institutional positioning. Mesoblast shareholders should stay informed on clinical trial outcomes, regulatory milestones, manufacturing partnerships, intellectual property developments, and competitor activity. These fundamental factors typically drive long-term institutional investment decisions more than transactional shareholding changes. The update on State Street’s substantial holder status offers context on institutional ownership but should be considered alongside Mesoblast’s operational and clinical progress.